We previously reported that PRMT1-mediated methylation of EGFR maintains its activation and promotes cell proliferation; increased EGFR methylation was correlated with worse survival in CRC patients who received cetuximab treatment [26]. The gene discussed is EGFR; the disease is colorectal carcinoma.